MACROGENICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.56 USD | +1.32% |
|
-6.73% | +51.35% |
| Apr. 26 | B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target | MT |
| Apr. 10 | North American Morning Briefing : Traders Await -2- | DJ |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 532.7 | 1,285 | 983.2 | 412.5 | 596.7 | 910.9 | - | - |
| Enterprise Value (EV) 1 | 316.9 | 1,104 | 983.2 | 412.5 | 366.9 | 833.9 | 910.9 | 910.9 |
| P/E ratio | -3.44 x | -9.26 x | -4.76 x | -3.44 x | -64.1 x | -5.83 x | -7.4 x | -4.87 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.3 x | 12.3 x | 12.7 x | 2.71 x | 10.2 x | 12.9 x | 6.48 x | 9.41 x |
| EV / Revenue | 4.94 x | 10.5 x | 12.7 x | 2.71 x | 6.25 x | 11.8 x | 6.48 x | 9.41 x |
| EV / EBITDA | -1.91 x | -9.25 x | -5.13 x | -3.77 x | -2.31 x | -4.64 x | -10 x | -5.63 x |
| EV / FCF | -2.24 x | -9.37 x | -6.55 x | -4.55 x | -4.59 x | -6.52 x | -7.42 x | -6.19 x |
| FCF Yield | -44.6% | -10.7% | -15.3% | -22% | -21.8% | -15.3% | -13.5% | -16.2% |
| Price to Book | 2.31 x | 4.05 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 48,958 | 56,204 | 61,258 | 61,475 | 62,029 | 62,561 | - | - |
| Reference price 2 | 10.88 | 22.86 | 16.05 | 6.710 | 9.620 | 14.56 | 14.56 | 14.56 |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 64.19 | 104.9 | 77.45 | 151.9 | 58.75 | 70.74 | 140.5 | 96.81 |
| EBITDA 1 | -166.3 | -119.4 | -191.5 | -109.6 | -158.6 | -179.5 | -91.07 | -161.8 |
| EBIT 1 | -177.2 | -131.1 | -202.8 | -121.4 | -168.2 | -167.6 | -125.2 | -202.6 |
| Operating Margin | -276.04% | -124.96% | -261.85% | -79.91% | -286.38% | -236.85% | -89.16% | -209.23% |
| Earnings before Tax (EBT) 1 | -151.8 | -129.7 | -202.1 | -119.8 | -9.058 | -169 | -117.4 | -218 |
| Net income 1 | -151.8 | -129.7 | -202.1 | -119.8 | -9.058 | -161.6 | -120.7 | -194.3 |
| Net margin | -236.51% | -123.7% | -260.97% | -78.82% | -15.42% | -228.47% | -85.93% | -200.68% |
| EPS 2 | -3.160 | -2.470 | -3.370 | -1.950 | -0.1500 | -2.496 | -1.968 | -2.993 |
| Free Cash Flow 1 | -141.4 | -117.8 | -150 | -90.58 | -79.97 | -127.9 | -122.8 | -147.3 |
| FCF margin | -220.35% | -112.32% | -193.72% | -59.62% | -136.12% | -180.85% | -87.45% | -152.11% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15.66 | 14.15 | 11.1 | 26.01 | 41.73 | 73.1 | 24.5 | 13.14 | 10.4 | 10.72 | 14.86 | 17.22 | 14.08 | 20.81 | 12.5 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | -47.45 | -47.55 | -45.79 | -44.11 | -42.08 | - |
| EBIT 1 | -52.99 | -58.24 | -66.64 | -41.81 | -24.96 | 11.98 | -38.43 | -44.96 | -35.5 | -49.35 | -43.54 | -43.29 | -49.36 | -40.66 | -57.6 |
| Operating Margin | -338.32% | -411.65% | -600.29% | -160.76% | -59.8% | 16.39% | -156.87% | -342.28% | -341.46% | -460.39% | -293.02% | -251.37% | -350.43% | -195.38% | -460.8% |
| Earnings before Tax (EBT) 1 | -52.89 | -58.02 | -66.44 | -41.3 | -24.81 | 12.8 | -38.01 | 57.47 | 17.55 | -46.07 | -43.51 | -42.01 | -48.88 | -37.95 | -57.6 |
| Net income 1 | -52.89 | -58.02 | -66.44 | -41.3 | -24.81 | 12.8 | -38.01 | 57.47 | 17.55 | -46.07 | -42.45 | -42.06 | -47.1 | -38.85 | -57.6 |
| Net margin | -337.67% | -410.14% | -598.53% | -158.82% | -59.46% | 17.51% | -155.16% | 437.49% | 168.84% | -429.78% | -285.72% | -244.22% | -334.39% | -186.69% | -460.8% |
| EPS 2 | -0.8600 | -0.9500 | -1.080 | -0.6700 | -0.4000 | 0.2100 | -0.6100 | 0.9200 | 0.2800 | -0.7500 | -0.6480 | -0.6383 | -0.7002 | -0.6041 | -0.9000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/24/22 | 5/3/22 | 8/8/22 | 11/3/22 | 3/15/23 | 5/9/23 | 8/9/23 | 11/6/23 | 3/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 216 | 181 | - | - | 230 | 77 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -141 | -118 | -150 | -90.6 | -80 | -128 | -123 | -147 |
| ROE (net income / shareholders' equity) | -64.1% | -49.3% | -75.5% | -62.8% | -6.15% | -259% | -137% | -63% |
| ROA (Net income/ Total Assets) | -47.1% | - | - | - | - | - | - | - |
| Assets 1 | 322.3 | - | - | - | - | - | - | - |
| Book Value Per Share | 4.710 | 5.640 | - | - | - | - | - | - |
| Cash Flow per Share | - | -2.130 | - | - | - | - | - | - |
| Capex 1 | 4.29 | 5.91 | 6.2 | 3.62 | 1.76 | 1.6 | 1.56 | 1.26 |
| Capex / Sales | 6.68% | 5.63% | 8.01% | 2.38% | 3% | 2.26% | 1.11% | 1.31% |
| Announcement Date | 2/25/20 | 2/25/21 | 2/24/22 | 3/15/23 | 3/7/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.56
USD
Average target price
24.8
USD
Spread / Average Target
+70.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.35% | 911M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MGNX Stock
- Financials MacroGenics, Inc.
